• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

    3.570 +0.010 (+0.28%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about SAB Biotherapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 Next >
    News headline image
    Top movers in Friday's session ↗
    Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
    Via Chartmill
    News headline image
    Which stocks are gapping on Friday? ↗
    The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
    Via Chartmill
    News headline image
    SAB BIO Highlights Data in Multiple Presentations at EASD
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Is SAB BIO Stock Trading Lower On Tuesday? ↗
    SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025. 
    Via Benzinga
    News headline image
    SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are moving before the opening bell on Wednesday? ↗
    Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    SAB BIO Announces Oversubscribed $175 Million Private Placement
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Gold Gains 1%; Boeing Shares Rise Following Q4 Results ↗
     
    Via Benzinga
    News headline image
    Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results ↗
     
    Via Benzinga
    News headline image
    Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings ↗
     
    Via Benzinga
    Topics Stocks
    News headline image
    SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Reports Full Year 2024 Operating and Financial Results
    SAB-142 Phase 1 trial positive topline data announced at KOL event 
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Participate in Upcoming Investor Conferences
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
    Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST 
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024 ↗
    SABS stock results show that SAB Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.